Tag: BIOR Stock

Free Live Daily Updates: AMC Short Interest Today + More

AMC Short Interest Today

Free Live Daily Updates: AMC Short Interest Today + More.

Community, I’m going to be updating this list of momentum stock and their short interest and utilization daily (AMC short interest, BBIG, MULN, BIOR, GME, APE, and many others).

Be sure to bookmark this page for daily AMC short interest updates and more.

Other metrics being updated daily will include the cost to borrow, shares on loan, + short squeeze scores.

If there are other heavily shorted stocks you’d like me to update daily, please leave a comment below and I’ll be sure to look into them before adding them to the list!

– Frank Nez

Franknez.com

#1. MMAT Short Interest

Short Interest: 10.38% | Utilization: 80.12 | Cost To Borrow: 18.93 | Shares On Loan: 37.76 Million | Days To Cover: 7.67

MMAT Short Squeeze Score: 84

(Updated Daily)

Market News Today - Senator Inquiries Now Grow on The MMTLP Scandal

Retweet This Article on Twitter โฌ‡๏ธ


#2. AMC Short Interest Today

Short Interest: 11.18% | Utilization: 59.73 | Cost To Borrow: 3.59 | Shares On Loan: 27.25 Million | Days To Cover: 1.90

AMC Short Squeeze Score: 65

(Updated Daily)

Retweet This Article on Twitter โฌ‡๏ธ


#3. GME Short Interest

Short Interest: 21.11% | Utilization: 84.45 | Cost To Borrow: 3.56 | Shares On Loan: 74.43 Million | Days To Cover: 25.81

(Updated Daily)

GME Short Squeeze Score: 86

Click the image to read the latest GameStop news article.

Retweet this article on Twitter โฌ‡๏ธ


#4. MULN SI

Short Interest: 20.64% | Utilization: 83.36 | Cost To Borrow: 23.35 | Shares On Loan: 82.54 million | Days To Cover: 1.29

(Updated Daily)

MULN Short Squeeze Score: 78

Mullen Announces It Has Now Delivered Its First Vehicles
Click the image to read the latest MULN stock news aritlce.

Repost this article on Twitter โฌ‡๏ธ


#5. LCID SI

Short Interest: 26.57% | Utilization: 95.07 | Cost To Borrow: 7.63 | Shares On Loan: 342.25 Million | Days To Cover: 8.59

(Updated Daily)

LCID Short Squeeze Score: 82

Daily Market News โ˜•

FrankNez - Daily Market News and stock updates.
FrankNez – Daily Market News and stock updates.

For more stock market, business news and updates, join the newsletter to receive weekly market news and notifications straight to your inbox.

Franknez.com is the media blog that keeps retail investors informed.

You can also follow me on TwitterInstagramFacebook, or LinkedIn for daily posts.

Related: This is What’s Stopping AMC From Squeezing Today



Top 5 Stocks Outperforming the Market Already This Year

Stock Market 2023: Top stocks outperforming the SPY.
Stock Market 2023: Top stocks outperforming the SPY.

The SPY is currently up +9.44% entering the second month of the year.

Shares of the S&P 500 index are trading at $416.78 at the time of this publication.

Last year, the index came down more than -10% bringing many companies down -50% to more than -80% on the year.

Today, stocks seem to be doing much better than experts and analysts anticipated.

Short sellers are currently down $81 billion this year-to-date.

Despite coming from a bear market, and all signs signaling an upcoming recession, early investors in some stocks are already killing it.

Here are 5 stocks currently outperforming the market already this year.

  1. Biora Therapeutics (NASDAQ:BIOR) +73.62%
  2. AMC Entertainment (NYSE:AMC) +54.71%
  3. AMC Preferred Equity (NYSE:APE) +135.83%
  4. Peloton Interactive (NASDAQ:PTON) +109.11%
  5. Tesla Inc. (NASDAQ:TSLA) +74.16%

#1. Biora Therapeutics (BIOR) Stock

Stock Market 2023: Top stocks outperforming the SPY.

Biora Therapeutics (NASDAQ:BIOR), formerly known as Progenity (PROG) stock was up more than +182% in the first week of the new year.

Today, BIOR stock is up more than +73% this year.

The stock surged from $2 per share and peaked around $7.36 last in only the second week of the new year.

BIOR is extremely shorted, weโ€™re talking about the company being one of the most shorted stocks in the market at the moment.

Ortex is reporting the company to have a whopping 243.95% short interest.

Why did BIOR stock surge so much this year already?

Biora Therapeutics is on track to move into clinic with its lead targeted therapeutics program.

If approved, it will be massive for the company and for shareholders alike.

Read More BIOR Stock News Here

#2. AMC Entertainment (AMC) Stock

Stock Market 2023: Top stocks outperforming the SPY.

AMC Entertainment (NYSE:AMC) stock continues to be one of the biggest ‘meme stocks’ even after its massive debut in 2021 when shares rose from $2.50 to $72 later that year.

The stock, at the publication of this article, is trading at $6.08, the same share price it was two years ago before gaining serious traction.

AMC Entertainment continues to improve its fundamentals and remains the #1 leader in the movie theatre industry.

While online streaming has grown to become quite popular, especially during the pandemic, experts are beginning to weigh in on AMC’s side in 2023.

CNBC stated, โ€œNetflix has backtracked on its previous policies, including by introducing an ad-supported subscription option, leading many to wonder whether the company should rethink its resistance to the traditional Hollywood movie release model as it looks for new ways to grow revenue.

Even Amazon associates who asked not to be identified, per Bloomberg News, are stating the company plans to invest $1 billion per year in the movie theatre industry.

The worldโ€™s largest online retailer aims to make between 12 and 15 movies annually that will get a theatrical release.

โ€œWhile a $1 billion annual investment for film development is on the lower end of what major Hollywood studios spend each year, itโ€™s a positive sign for the movie theater business, which has struggled in the wake of the pandemic”, said CNBC.

#3. AMC Preferred Equity (APE)

AMC Preferred Equity (NYSE:APE) is currently up +135.83% this year-to-date.

The equity made its debut in August of 2022 as a dividend for AMC shareholders.

AMC Entertainment has been able to capitalize on the equity by using funds to pay off debt and raise capital for the company.

Shares have plummeted since its inception; however, we’re seeing APE shares outperform the market too.

Plans to merge APE shares with AMC common stock will soon be up for shareholders to vote on.

Also Read: AMC Warns Short Sellers of Possible APE Short Squeeze

#4. Peloton (PTON) Stock

Peloton Interactive, Inc. (NASDAQ:PTON) is an American exercise equipment and media company based in New York City.

The company’s products are stationary bicycles, treadmills, indoor rowers equipped with Internet-connected touch screens that stream live and on-demand fitness classes through a subscription service.

Company shares are up +109.11% year-to-date.

Peloton recently brought Leslie Berland, Twitter’s former marketing head, as its next chief marketing officer, per Bloomberg news reports.

She previously helped lead American Express for 10 years.

Peloton is trying to shift the tides after a rough 2022, when its stock dropped more than 75%.

The company in November posted wider losses than analysts expected for its first fiscal quarter.

Berland said in an announcement that she is โ€œthrilledโ€ to join the company at this โ€œunique moment in its transformation journey.โ€

Read More Market News Here

#5. Tesla Inc. (TSLA) Stock

Stock Market 2023: Top stocks outperforming the SPY.
Stock Market 2023: Top stocks outperforming the SPY.

Tesla Inc. (NASDAQ:TSLA) had one of its worst years yet in 2022.

However, the company stock is outperforming the market today already gaining +74.16% in gains this year-to-date.

Tesla CEO Elon Musk sold 22 million shares of the company last year cashing in approximately $3.6 billion earlier in December according to this SEC filing.

After the massive selloff, Elon said during a Twitter space call that he will not sell any Tesla shares for about two years.

Musk said he sees a โ€˜seriousโ€™ recession in 2023 and is preparing for a worst-case scenario.

And although experts are saying a recession is likely to strike the U.S. economy during the first quarter of 2023, the company stock seems to be performing quite well today.

Related: Is Tesla Stock a Buy Right Now or Should You Wait?

Honorable mentions

#6. Hycroft Mining Holding (HYMC) Stock

Shares of Hycroft Mining (NASDAQ:HYMC) rose 25% earlier this year when the company announced it had discovered more gold and silver than it had anticipated.

Majority of the company is owned by AMC Entertainment.

22% of the company to be exact.

When the movie theatre chain acquired the mining company, headquartered in Nevada, shareholders followed.

Hycroft was able to raise an incredible $195 million in just two weeks after the acquisition.

Today, company shares are up nearly +10.31% year-to-date.

#7. GameStop Corp. (GME) Stock

GameStop Corp. (NYSE:GME) shares are currently up +31.98% year-to-date.

GME stock continues to be a retail investors favorite despite its popularity coming down since the ‘meme stock’ frenzy of 2021.

Today, shareholders are registering their shares through DRS to prevent short sellers from attacking the company stock.

According to GameStop, approximately 30% of GMEโ€™s float is registered with the Direct Registration System (DRS).

This equates to 71.3 million retail shares.

How much of GMEโ€™s float is owned by retail investors?

Nearly 70% of the float is owned by individual shareholders according to Vickers Stock Research.

While DRS certainly prevents the company from being shorted, itโ€™s only one piece of the puzzle for a GameStop short squeeze.

Shareholders will need to create massive buying pressure next.

Read More About GameStop and DRS Here

Check out the latest market news for retail investors!

Franknez.com - Business news, Market News, Analysis, + more.
Franknez.com – Business news, Market News, Analysis, + more.

For more stock, business news and updates, join the newsletter to receive weekly market news and notifications straight to your inbox.

Or follow me on TwitterInstagramFacebook, and LinkedIn for daily posts.


Franknez.com

You can now read exclusive FrankNez articles for only $1/mo.

  • Gain access to EXCLUSIVE FrankNez articles you wonโ€™t find here.
  • Become part of a private and safe Discord community, just for retail investors.
  • Get drawn at the end of the year for holiday giveaways.

BIOR Short Interest Rises to More Than 243%

BIOR stock news
FrankNez News: BIOR short interest rises | BIOR stock news today.

Biora Therapeutics (NASDAQ:BIOR) short interest has risen to more than 243%.

More than double the company’s float is being shorted by big financial institutions.

BIOR stock is up more than +71% this year-to-date but surged as much as +182% during the first trading week of January.

Formerly known as ‘Progenity’ (PROG), Biora Therapeutics stock is currently trading at $4.12.

The company may be heavily shorted, but there’s big opportunity for retail investors if the company’s clinical trials go well.

And so far, the company seems to be on track.

A big announcement such as the approval of their therapeutics program could trigger short sellers to run for the hills, initiating a short squeeze in Biora Therapeutics.

Will BIOR stock go up to its hundreds of dollars per share IPO levels again?

Here’s the latest BIOR stock news.

BIOR Stock News Today

BIORA Therapeutics
BIOR Stock Short Interest + news today.

Biora Therapeutics is on track to move into clinic with its lead targeted therapeutics program.

For Bioraโ€™s Targeted Therapeutics Platform, which is focused on treatment of ulcerative colitis (UC), the company remains on track for an IND filing for its PGN-600 program followed by clinical trial initiation.

During Q4 2022, Biora continued its engagement with the FDA with a pre-IND supplemental Type C filing requesting agency feedback on its proposed PGN-600 clinical development plans, including the companyโ€™s proposed approach to toxicity studies and other aspects of its clinical plan.

โ€œThe recent Type C response from the FDA further strengthens our confidence in our plans to enter the clinic during the first half of 2023 with IND filing followed by trial initiation in Q2, and data readouts anticipated in Q3,โ€ said Adi Mohanty, Chief Executive Officer of Biora Therapeutics.

For Bioraโ€™s Systemic Therapeutics program, the company has been transitioning from early concept to a clinical-ready device.

With several of the key device upgrades implemented, the company expects to report data from preclinical studies on its next-generation device during Q1 and Q2 of 2023.

If clinical trials prove to be a success, Biora Therapeutics’ platform will be approved for use.

Source(s): Yahoo Finance

Will BIOR Stock Go to $100 Per Share?

BIOR Stock Price Today - BIOR Short Interest news and updates.
BIOR Stock Price Today – BIOR Short Interest news and updates.

Analysts are giving BIOR stock a high stock price prediction of $100 in the next 12-months, thatโ€™s a +2,045% gain.

Price targets for BIOR look rather promising, at least according to the experts.

CNN is showing the biotech company has a medium stock forecast of $82.50 (+1,670%) and a low of $65 (+1,294%).

So, is BIOR stock a buy?

Based on expert price targets for 2023, Biora Therapeutics stock could prove to be a โ€˜buyโ€™ for value long term investors.

You can also keep an eye on Biora Therapeutic’s short interest updated daily here.

Read the latest Market News

For more stock market, business news and updates, join the newsletter to receive weekly market news and notifications straight to your inbox.

Franknez.com is the media blog that keeps retail investors informed.

You can also follow me on TwitterInstagramFacebook, or LinkedIn for daily posts.


Franknez.com

You can now read exclusive FrankNez articles for only $1/mo.

  • Gain access to EXCLUSIVE FrankNez articles you wonโ€™t find here.
  • Become part of a private and safe Discord community, just for retail investors.
  • Get drawn at the end of the year for holiday giveaways.

Is Biora Therapeutics (BIOR) Stock About to Go Big?

PROG Stock
Stock Market News: Is Biora Therapeutics (BIOR) stock about to squeeze?

Biora Therapeutics (NASDAQ:BIOR), formerly known as PROG stock was up more than +182% in the first week of the new year.

Today, BIOR stock is up more than +98% this year.

The stock surged from $2 per share and peaked around $7.36 last Wednesday but closed at $6.70.

After hours, the stock experienced a -10% pullback.

Today, BIOR is trading at $4.66.

Is Biora Therapeutics (BIOR) stock only warming up for takeoff?

BIOR is extremely shorted, we’re talking about the company being one of the most shorted stocks in the market at the moment.

Ortex is reporting the company to have a whopping 243.95% short interest.

What makes this stock even more interesting is that on Wednesday, massive buying volume came out of the blue.

Was this rally the first domino to fall that will trigger a BIOR short squeeze soon?

Let’s break it all down below.

BIOR (PROG) Stock Short Interest Today

Biora Therapeutics (PROG) stock has a current short interest of 195.74% with approximately 1.20 day to cover, per Fintel and 243% per Ortex.

Dark pool volume has eaten more than 54% of intraday trading volume.

However, trading volume has been quite strong in the past weeks.

BIOR stock price today
Biora Therapeutics (PROG) Stock Price Today.

So, why the sudden volume surge?

Did shorts begin to close their positions due to an upcoming catalyst?

This could very well be true, as BIOR just released an update that could potentially put their extraordinary work to real-world use.

And if all goes according to plan, shareholders may expect a massive short squeeze from BIOR (NASDAQ:BIOR).

The latest Biora Therapeutics news has the potential to create a big drop in short interest, sending share prices skyrocketing.

Latest BIOR Stock News (PROG)

PROG Stock News
Biora Therapeutics (BIOR) stock news | PROG stock news.

Biora Therapeutics is on track to move into clinic with its lead targeted therapeutics program.

For Bioraโ€™s Targeted Therapeutics Platform, which is focused on treatment of ulcerative colitis (UC), the company remains on track for an IND filing for its PGN-600 program followed by clinical trial initiation.

During Q4 2022, Biora continued its engagement with the FDA with a pre-IND supplemental Type C filing requesting agency feedback on its proposed PGN-600 clinical development plans, including the companyโ€™s proposed approach to toxicity studies and other aspects of its clinical plan.

โ€œThe recent Type C response from the FDA further strengthens our confidence in our plans to enter the clinic during the first half of 2023 with IND filing followed by trial initiation in Q2, and data readouts anticipated in Q3,โ€ said Adi Mohanty, Chief Executive Officer of Biora Therapeutics.

Biora Therapeutics has previously shown the strong potential of its Targeted Therapeutics platform to help patients with ulcerative colitis (UC) through data demonstrating that:

For Bioraโ€™s Systemic Therapeutics program, the company has been transitioning from early concept to a clinical-ready device.

With several of the key device upgrades implemented, the company expects to report data from preclinical studies on its next-generation device during Q1 and Q2 of 2023.

This is big news for the company and for BIOR shareholders alike.

The latest PROG stock news could be the reason why we’ve been seeing bullish price action this year.

If clinical trials prove to be a success, Biora Therapeutics’ platform will be approved for use.

This could yield a massive payout for shareholders invested in the company this year, a PROG short squeeze.

Source(s): Yahoo Finance

BIOR Stock Forecast: Is BIOR Stock a Buy?

Analysts are giving BIOR stock a high stock price prediction of $100 in the next 12-months, that’s a +2,045% gain.

Price targets for BIOR look good overall.

CNN is showing the biotech company has a medium stock forecast of $82.50 (+1,670%) and a low of $65 (+1,294%).

So, is BIOR stock a buy?

Based on expert price targets for 2023, Biora Therapeutics stock could prove to be a ‘buy’ for value long term investors.

Are you holding Biora Therapeutics stock?

Biora Therapeutics News
Biora Therapeutics News – Franknez.com.

Is this the catalyst shareholders have been waiting for?

Leave your thoughts below for the retail community to see.

For more PROG stock news and updates, join the newsletter to receive weekly market news and notifications straight to your inbox.

Or follow me on Twitter, Instagram, Facebook, or LinkedIn for daily posts.

Read the Latest Market News Here


Franknez.com

You can now support the blog for only $1/mo.

  • Gain access to EXCLUSIVE FrankNez articles you wonโ€™t find here.
  • Become part of a private and safe Discord community, just for retail investors.
  • Get drawn at the end of the year for holiday giveaways.
    • Members have won FREE merch and AirPods.

© 2023 Franknez.com

Theme by Anders NorenUp ↑